MFOLFIRINOX is named as a drug or biological intervention in 12 clinical trials in our USA, China and UK trial registers, 8 of which are recruiting. Lead sponsors include Incyte Corporation (2), Genentech, Inc. (1) and EMD Serono Research & Development Institute, Inc. (1). Registered phases: Phase 1, Phase 2, Phase 1/2 and Phase 2/3. Conditions studied include PDAC - Pancreatic Ductal Adenocarcinoma; Solid Tumors; CRC (Colorectal Cancer).
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| PDAC - Pancreatic Ductal Adenocarcinoma | 3 |
| Solid Tumors | 2 |
| CRC (Colorectal Cancer) | 2 |
| PDAC | 2 |
| NSCLC | 2 |
| Pancreatic Ductal Adenocarcinoma | 2 |
| Adenocarcinoma, Pancreatic Ductal | 1 |
| Advanced Solid Tumor | 1 |
| Cancer | 1 |
| NSCLC (Non-small Cell Lung Cancer) | 1 |
| RAS Mutation | 1 |
| Colorectal Cancer | 1 |
| CRC | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Metastatic Pancreatic Adenocarcinoma | 1 |
| Pancreatic Cancer | 1 |
| Radiotherapy | 1 |
| Pancreatic Cancer Resectable | 1 |
| Lead sponsor | Trials |
|---|---|
| Incyte Corporation | 2 |
| Genentech, Inc. | 1 |
| EMD Serono Research & Development Institute, Inc. | 1 |
| Alterome Therapeutics, Inc. | 1 |
| Tango Therapeutics, Inc. | 1 |
| Revolution Medicines, Inc. | 1 |
| Oncotelic Inc. | 1 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
| Fudan University | 1 |
| Sun Yat-sen University | 1 |
| Register | MFOLFIRINOX trials |
|---|---|
| Clinical trials in USA | 10 |
| Clinical trials in China | 2 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how MFOLFIRINOX works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MFOLFIRINOX (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.